Better Outcomes for Ovarian Cancer Associated With the Detection of Anti‐EBV TCR CDR3s: Potential Relevance to Diffuse Large B‐Cell Lymphoma

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1111/aji.70046

ABSTRACT

Objectives

Given the ongoing challenges regarding the specific roles of viral infections in cancer etiology, or as cancer co‐morbidities, this study assessed potential associations between anti‐viral, T‐cell receptor (TCR) complementarity domain region‐3 (CDR3s), and clinical outcomes for ovarian cancer.

Methods

TCR CDR3s were isolated from ovarian cancer specimens for a determination of which patients had anti‐viral CDR3s and whether those patients had better or worse outcomes.

Results

Analyses revealed that patients with exact matches of anti‐Epstein–Barr virus (EBV) CDR3 amino acid sequences exhibited better outcomes for both overall and disease‐specific survival. However, better outcomes were not observed when assessing anti‐viral CDR3s representing cytomegalovirus, influenza A, or Sars‐CoV‐2. Due to previous occurrences of the occasional misdiagnoses of lymphoma as ovarian cancer, the frequency of anti‐EBV CDR3s in lymphoma patients was determined. These frequencies were relatively high, particularly for diffuse large B‐cell lymphoma.

Conclusions

These findings (i) underscore the potential value of anti‐EBV immune responses in terms of patient outcomes; (ii) raise questions about the potential value of anti‐EBV immunotherapies; and (iii) support further inquiry into the relationship between EBV infection and previously reported cases of ovary‐resident lymphoma.